Pyxis Oncology
PYXS
79 hedge funds and large institutions have $34.7M invested in Pyxis Oncology in 2025 Q4 according to their latest regulatory filings, with 22 funds opening new positions, 25 increasing their positions, 18 reducing their positions, and 14 closing their positions.
579% more call options, than puts
Call options by funds: $584K | Put options by funds: $86K
57% more first-time investments, than exits
New positions opened: 22 | Existing positions closed: 14
39% more repeat investments, than reductions
Existing positions increased: 25 | Existing positions reduced: 18
8% more funds holding
Funds holding: 73 → 79 (+6)
5.24% more ownership
Funds ownership: 43.26% → 48.5% (+5.2%)
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
42% less capital invested
Capital invested by funds: $59.7M → $34.7M (-$25M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
LCM
Laurion Capital Management
New York
|
+$4.13M |
| 2 |
HP
HealthInvest Partners
Stockholm,
Sweden
|
+$2.18M |
| 3 |
Jane Street
New York
|
+$1.7M |
| 4 |
Marshall Wace
London,
United Kingdom
|
+$1.37M |
| 5 |
6CM
683 Capital Management
New York
|
+$1.29M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
TCM
Tang Capital Management
San Diego,
California
|
-$5.55M |
| 2 |
PA
Perceptive Advisors
New York
|
-$2.62M |
| 3 |
SC
Stempoint Capital
New York
|
-$1.53M |
| 4 |
DCM
Driehaus Capital Management
Chicago,
Illinois
|
-$929K |
| 5 |
SC
Schulhoff & Co
Cincinnati,
Ohio
|
-$611K |
PYXS Hedge Fund Activity: Q4 2025 in Review
79 of the 8,225 institutional investors tracked by Wall St. Rank reported a position in Pyxis Oncology (PYXS) for Q4 2025, worth a combined $34.7M — down 42% from $59.7M a quarter earlier.
Buyers outnumbered sellers: 22 funds opened new PYXS positions and 14 closed out — a net gain of 8 holders — while 25 added to existing stakes and 18 trimmed.
The largest buyer was Laurion Capital Management, adding an estimated $4.13M. The largest seller was Tang Capital Management, exiting entirely with an estimated $5.55M sold.
- 79 institutional investors held Pyxis Oncology (PYXS) as of Q4 2025, up from 73 in Q3 2025.
- Funds reported $34.7M of Pyxis Oncology stock for Q4 2025, down 42% quarter-over-quarter.
- 22 funds opened new Pyxis Oncology positions in Q4 2025 and 14 closed out, a net change of +8 holders.
- The largest Pyxis Oncology buyer in Q4 2025 was Laurion Capital Management, an estimated $4.13M added.
- The largest Pyxis Oncology seller in Q4 2025 was Tang Capital Management, an estimated $5.55M sold.
Based on aggregated 13F filings for Q4 2025.